Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMN for Physical Frailty in Diabetic Older Adults
jRCTs051190002Completed
- Sponsor
- Teijin
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in Fragility and type 2 diabetes mellitus (T2DM) comparing NMN 250 mg with Placebo (2 arms). Primary endpoints: Change in grip strength at final evaluation and Change in walking speed at final evaluation. Started Apr 2019; status: completed.
02
Drugs
nicotinamide mononucleotide
03
Conditions
Fragilitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051190002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190002.